Table 1.
Demographics, Lung Function and Symptoms of 264 Respiratory Outpatients with Bronchiectasis Followed for 5 Years at Two University Hospitals
Demographics | N = 264a | ||
---|---|---|---|
Age (years) | 66 (51–72) | ||
Female | 165 (62%) | ||
BMI (kg/m2) | 24.5 (21.8–27.1, N=226) | ||
Smoking Status | |||
Never Smokers | 112 (45%) | ||
Ex-Smokers | 117 (47%) | ||
Current Smokers | 22 (8.8%) | ||
Pack-Years | 15 (2–30, N=139) | ||
BSI Score | 6.0 (5.0–9.0, N=86) | ||
COPD Diagnosis | 65 (25%) | ||
Asthma Diagnosis | 72 (27%) | ||
Aetiologiesb | |||
Allergic Bronchopulmonary Aspergillosis | 15 (5.7%) | ||
Connective Tissue Disease | 31 (12%) | ||
Inflammatory Bowel Disease | 17 (6.7%) | ||
Childhood Severe Pulmonary Disease | 30 (11%) | ||
Immunosuppression (Idiopathic and Pharmacologic) | 12 (4.8%) | ||
Idiopathic Bronchiectasis | 177 (67%) | ||
Lung Function and Symptoms | No ICS, N = 139 | ICS-Treated, N = 122a | p-valuec |
FEV1 (L) | 2.22 (1.79–2.80) (N=131) | 1.71 (1.31–2.33) (N=118) | <0.001 |
% Predicted | 80.9 (71.2–93.1) (N=119) | 65.2 (48.6–83.1) (N=104) | <0.001 |
FVC | 2.90 (2.42–3.48) (N=128) | 2.56 (1.97–3.30) (N=116) | 0.003 |
% Predicted | 82.5 (68.8–89.6) (N=118) | 75.2 (59.0–87.3) (N=104) | 0.010 |
FEV1/FVC ratio | 0.77 (0.71–0.81) (N=128) | 0.70 (0.59–0.78) (N=116) | <0.001 |
>0.8 | 39 (30%) | 22 (19%) | 0.038 |
<0.7 | 22 (17%) | 59 (51%) | <0.001 |
Chronic Cough | 109 (71%, N=134) | 103 (91%, N=113) | 0.028 |
Chronic Sputum Production | 91 (71%, N=129) | 100 (89%, N=112) | <0.001 |
Chronic Dyspnoea | 43 (34%, N=126) | 68 (64%, N=107) | <0.001 |
Chronic Sinusitis | 8 (7.6%, N=105) | 6 (8.7%, N=69) | 0.8 |
Notes: aStatistics presented: median (interquartile range); n (%). N denotes number of patients with data available. bSum >100% due to multiple possible aetiologies per patient. cStatistical tests performed: Wilcox test; chi-squared.
Abbreviations: BSI, Bronchiectasis Severity Index; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; ICS, inhaled corticosteroids.